Chelsea Therapeutics is committed to developing novel therapeutic agents that address disease states that correspond to significant unmet medical need.

Our pipeline also includes a library of metabolically inert antifolate medications, including a clinical-stage product, CH-4051, for the treatment of rheumatoid arthritis and other autoimmune diseases.

OUR R&D PIPELINE
CompoundIndicationPhase IPhase IIPhase IIINDA Submitted
NDA Approved
DroxidopaSymptomatic Neurogenic Orthostatic Hypotension
DroxidopaIntradialytic Hypotension
DroxidopaFibromyalgia
CH-4051Rheumatoid Arthritis